{"organizations": [], "uuid": "13a95ed1882d2854d5e88d6b356b1cc71afcc30a", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-soligenix-driving-towards-key-infl/brief-soligenix-driving-towards-key-inflection-points-with-two-pivotal-phase-3-clinical-trials-idUSASB0C2BQ", "country": "US", "domain_rank": 408, "title": "BRIEF-Soligenix - Driving Towards Key Inflection Points With Two Pivotal Phase 3 Clinical Trials", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-25T14:38:00.000+02:00", "replies_count": 0, "uuid": "13a95ed1882d2854d5e88d6b356b1cc71afcc30a"}, "author": "", "url": "https://www.reuters.com/article/brief-soligenix-driving-towards-key-infl/brief-soligenix-driving-towards-key-inflection-points-with-two-pivotal-phase-3-clinical-trials-idUSASB0C2BQ", "ord_in_thread": 0, "title": "BRIEF-Soligenix - Driving Towards Key Inflection Points With Two Pivotal Phase 3 Clinical Trials", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "clinical trials reuters", "sentiment": "none"}, {"name": "soligenix inc", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": " 40 PM / Updated 22 minutes ago BRIEF-Soligenix - Driving Towards Key Inflection Points With Two Pivotal Phase 3 Clinical Trials Reuters Staff 1 Min Read \nJan 25 (Reuters) - Soligenix Inc: \n* SOLIGENIX - DRIVING TOWARDS KEY INFLECTION POINTS WITH TWO PIVOTAL PHASE 3 CLINICAL TRIALS Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-01-25T14:38:00.000+02:00", "crawled": "2018-01-25T15:06:34.027+02:00", "highlightTitle": ""}